Briefs: NATCO Pharma, Mylan Pharmaceuticals, Novo Nordisk and Alembic Pharmaceuticals

Mylan and Novo Nordisk reach settlement of US patent litigation related to Ozempic

Jubilant Ingrevia becomes only Indian company to join WEF’s Global Lighthouse Network

WEF recognises company’s Bharuch manufacturing facility as a global manufacturing lighthouse

Jubilant Biosys signs and issues a put option offer to Pierre Fabre Laboratories

The acquisition will strengthen the overall company’s position as leading global CRO services partner

Dr. Reddy’s Laboratories Switzerland incorporates a subsidiary in Denmark

he company will focus on production of any pharmaceutical and biotechnological products

Alembic Pharmaceuticals receives USFDA final approval for Lamotrigine Extended-Release Tablets

Lamotrigine extended-release tablets are indicated for adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures

Clariant to launch eight new high-performing excipients at the CPHI Milan 2024

Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines

Chemify gets grant to design and discover new drug leads for Tuberculosis and Malaria

Grant funding from the Bill & Melinda Gates Foundation will support the rapid and efficient design and synthesis of novel small molecules

Morepen Laboratories appoints Amrit Ravi as Vice President

He holds a Master’s in Management from the National University of Singapore

Piramal Pharma Solutions announces US$ 80 million expansion plan for Sterile Injectables facility in Kentucky

USFDA inspection update on Jubilant HollisterStier’s Montreal facility

HSGP is engaged closely with the USFDA and is committed to address the OAI observations through planned remediation measures